CoChat

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma

Open access
Sayour, Elias J., McLendon, Pat, McLendon, Roger, De Leon, Gabriel, Reynolds, Renee, Kresak, Jesse, Sampson, John H., Mitchell, Duane A. · 2015 · Cancer Immunology, Immunotherapy

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Glioblastoma multiforme (GBM) is an aggressive malignancy associated with profound host immunosuppression mediated in part by FoxP3 expressing regulatory CD4+ T lymphocytes (Tregs) that down-regulate anti-tumor immunity. In order to assess whether FoxP3 was an independent driver differentially expressed in primary versus recurrent GBMs, we stained resected primary and recurrent GBM tumors for CD3, CD4, CD8 and FoxP3 expression using standard immunohistochemistry. Slides were scanned with a high-resolution scanner (ScanScope CS; Aperio), and image analysis software (Aperio ScanScope) was used to enumerate lymphocyte subpopulations allowing for high-throughput analysis and bypassing manual selection bias. As shown in previous studies, enumeration of individual lymphocyte populations did not correlate with clinical outcomes in patients with GBM. However, the CD4+ to regulatory FoxP3+ T cell ratio was diminished in recurrent disease, and increased CD3 and CD8+ to regulatory T cell ratios showed a positive correlation with survival outcomes in primary GBM. These results suggest that while absolute numbers of tumor infiltrating lymphocytes may not be informative for predicting clinical outcomes in patients with GBM, the effective balance of CD3, CD4 and CD8+ T cells to immunosuppressive FoxP3+ regulatory cells may influence clinical outcomes in this patient population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-014-1651-7

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

Metadata

Authors
Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A.
Affiliations
  • University of Florida (US)
  • Duke University (US)
  • Duke Medical Center (US)
Corresponding author
Mitchell, Duane A.
Venue
Cancer Immunology, Immunotherapy
Published
2015-01-03
Volume
64
Issue
4
Pages
419-427
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2066684749
Cited by
196
References
42
Citations by year
2026: 9 · 2025: 14 · 2024: 14 · 2023: 15 · 2022: 15 · 2021: 28 · 2020: 21 · 2019: 17 · 2018: 20 · 2017: 18 · 2016: 16 · 2015: 8
FWCI
11.57
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001427, 5r01ca134844-04)
  • National Cancer Institute (5R01-CA134844, R01-CA235612, R01-CA134844, P50CA108786)
  • National Institute of Neurological Disorders and Stroke (R01NS067037, 5R01-NS067037)
  • National Center for Research Resources (UL1RR024128)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
glioblastoma, Foxp3+ regulatory T cells, tumor-infiltrating lymphocytes, tumor recurrence, survival, CD4+ T cells, CD8+ T cells, CD3+ T cells, tumor immunosuppression, antitumor immunity, prognostic factors
MeSH terms
Adult, Aged, Brain Neoplasms, Female, Follow-Up Studies, Glioblastoma, Humans, Immunoenzyme Techniques, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Survival Rate, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Forkhead Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.